Neupogen (Filgrastim)

Filgrastim, the active ingredient in Neupogen, is a granulocyte colony-stimulating factor presented as an injection solution for subcutaneous use. It treats chemotherapy‑induced neutropenia and other neutropenic conditions in patients receiving cancer therapy, bone‑marrow transplantation, or with severe chronic neutropenia.

GNH USA supplies Neupogen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Neupogen (filgrastim) is used to manage neutropenia, a condition of low neutrophil counts, across several clinical settings.

- Chemotherapy‑induced neutropenia: reduces the duration of neutropenia and lowers infection risk in patients receiving cytotoxic chemotherapy. - Neutropenia associated with bone marrow transplantation: supports neutrophil recovery after hematopoietic stem cell transplant. - Severe chronic neutropenia or agranulocytosis: increases neutrophil production in patients with persistent low counts.

Neupogen may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Bone pain: mild to moderate discomfort in bones or joints. - Injection site reactions: redness, swelling, or itching at the injection site. - Fever: transient elevation in body temperature. - Headache: mild headache.

Serious or Rare Side Effects: - Splenic rupture: rare but potentially life‑threatening. - Acute respiratory distress syndrome (ARDS): severe lung inflammation. - Allergic reactions: anaphylaxis, urticaria, or angioedema.

When prescribing Neupogen, clinicians should consider several safety and handling precautions.

- Indication verification: ensure neutropenia is confirmed and the patient meets approved criteria. - Monitoring blood counts: perform regular complete blood counts to track neutrophil response. - Bone pain management: assess and treat bone pain, which may require analgesics. - Splenic assessment: monitor for abdominal pain that could indicate splenic enlargement. - Concomitant chemotherapy: adjust timing relative to cytotoxic agents to avoid overlapping toxicities. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Neupogen can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Chemotherapy agents with overlapping myelosuppressive effects: may reduce benefit of filgrastim. - High‑dose corticosteroids: can blunt neutrophil response. - Antimicrobial agents that cause neutropenia: concurrent use may counteract intended effect.

Moderate Interactions (Monitor Closely): - Immunosuppressants (e.g., cyclosporine): monitor neutrophil counts. - Live attenuated vaccines: assess infection risk due to altered immune response. - Lithium: may enhance leukocytosis, requiring blood count monitoring.